Опыт применения эхоконтрастного препарата Соновью в дифференциальной диагностике опухолей почки. Часть 2

Sufficient experience of differential diagnostics of focal renal lesions according to contrast-enhanced ultrasound is accumulated in the world now, however, only the own experience of use of this agent gives the chance of accumulation of the corresponding knowledge and skills. Objective : to estimate the possibilities of SonoVue contrast agent for differential ultrasonic diagnostics of focal renal lesions and to compare the obtained data with results of morphology. Materials and methods. During the period from March, 2015 to September, 2016 at A.V. Institute of surgery 47 patient with focal renal lesdions have been surveyed and were operated on. There were 27 (57.4%) men and 20 (42.6%) women aged from 19 up to 66 years. All patient carried out ultrasonography in B-mode, duplex scanning, three-dimensional reconstruction of the ultrasonic image, and contrast-enhanced research with SonoVue agent was carried out also. All neoplasms were morphologically verified: clear cell carcinoma – 34 (72.4%); papillary cancer – 5 (10.6%); chromophobe cancer – 1 (2.1%); juxtaglomerular cell tumor – 1 (2.1%); oncocytoma – 1 (2.1%); adenoma – 2 (4.3%); chronic inflammatory infiltrate – 1 (2.1%); a cyst – 2 (4.3%). We consider to take up expedient separately questions of diagnosis of light-cellular cancer and rare forms of kidney and cellular cancer. Results. Part 2 . Observations of US with contrastenhanced of rare morphological forms of benign and malignant renal tumors of in comparison to results of morphological researches are presented. It allows to study the nature of tumors bloodsupply in more detail, that gives the chance to provide their differentiation. Further accumulating of material and the analysis of bigger data array for development of own line item concerning opportunities of verification of rare renal tumors according to US with contrastenhanced are reasonably. Conclusion. Contrast-enhanced ultrasonography with SonoVue agent is rather cheap, doesn't bear beam load of the patient and isn't nephrotoxic owing to what it is expedient to include it in the protocol of inspection of patients with suspicion of renal cancer.